Pre-clinical CRO ZHSK Lab Nets Over CNY 100 Mn in Series B

Healthcare Author: Lingxi Peng Editor: Mianmian Wang Dec 01, 2022 09:57 AM (GMT+8)

ZSHK, a pre-clinical Contract Research Organization (“Preclinical CRO”), raised funds from AZ-CICC and its existing investor Jishi Capital to enhance international deployment and key resources construction


ZSHK Laboratories Limited (“ZSHK LAB”) (Chinese: 滬港中科), a pre-clinical CRO, announced the completion of a CNY 100 million (USD 712.25 million)Series B round of financing on 28 Nov, with investment led by AstraZeneca-CICC Healthcare Industrial Fund (Chinese: 阿斯利康中金医疗产业基金) and joined by its existing investor Jishi Capital (Chinese:济时资本). Proceeds will be mainly used for the advancement of the construction of key resources needed for novel drugs and preclinical medical device evaluation and the business development in HK and overseas.

ZSHK LAB is a pre-clinical CRO company mainly engaged in pre-clinical research and evaluation services for drugs and medical devices. Its core members include experienced toxicology research scientists, pharmacologists, immunology and experimental animal technical professionals, pathologists qualified by the CAP, enabling ZSHK LAB to serve as a one-stop evaluation and research service platform, providing services including pharmacology, pharmacodynamics, pharmacokinetics, toxicology and other safety-related studies for pharmaceutical developers and researchers worldwide.

Stimulated by government policy and the development of CRO industry, Chinese mode of new drug R&D is shifting from imitative innovation to original innovation. Taking this as an opportunity, Chinese CRO enterprises will engage in biopharmaceutical R&D earlier and more frequently. ZSHK, for example, has continually explored a more compatible research service mode by virtue of its active efforts in independent laboratories deploying. According to ZHSK LAB, it has established independent laboratories in Hong Kong Science and Technology Park, Pingshan District of Shenzhen, Guangdong Province, and Suzhou Industrial Park of Jiangsu Province and has established breeding and research bases of experimental dogs and non-human primates in Hunan and Guangxi.

ZSHK LAB's competitors include Wuxi AppTec (Chinese:药明康德),Pharmaron (Chinese:康龙化成), and Tigermed (Chinese:泰格医药).